These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25494662)

  • 1. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia.
    Mallappa A; Sinaii N; Kumar P; Whitaker MJ; Daley LA; Digweed D; Eckland DJ; Van Ryzin C; Nieman LK; Arlt W; Ross RJ; Merke DP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):1137-45. PubMed ID: 25494662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.
    Verma S; Vanryzin C; Sinaii N; Kim MS; Nieman LK; Ravindran S; Calis KA; Arlt W; Ross RJ; Merke DP
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):441-7. PubMed ID: 19486026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia.
    Jones CM; Mallappa A; Reisch N; Nikolaou N; Krone N; Hughes BA; O'Neil DM; Whitaker MJ; Tomlinson JW; Storbeck KH; Merke DP; Ross RJ; Arlt W
    J Clin Endocrinol Metab; 2017 Jun; 102(6):1797-1806. PubMed ID: 27845856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia.
    Nella AA; Mallappa A; Perritt AF; Gounden V; Kumar P; Sinaii N; Daley LA; Ling A; Liu CY; Soldin SJ; Merke DP
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4690-4698. PubMed ID: 27680873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.
    Ng SM; Stepien KM; Krishan A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012517. PubMed ID: 32190901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.
    Melin J; Parra-Guillen ZP; Michelet R; Truong T; Huisinga W; Hartung N; Hindmarsh P; Kloft C
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32052005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia.
    Prete A; Auchus RJ; Ross RJ
    Eur J Endocrinol; 2021 Nov; 186(1):R1-R14. PubMed ID: 34735372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia.
    Karunasena N; Margetson DN; Neal G; Whitaker MJ; Ross RJ
    Eur J Endocrinol; 2017 Apr; 176(4):405-411. PubMed ID: 28100629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
    Merza Z; Rostami-Hodjegan A; Memmott A; Doane A; Ibbotson V; Newell-Price J; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.
    Debono M; Mallappa A; Gounden V; Nella AA; Harrison RF; Crutchfield CA; Backlund PS; Soldin SJ; Ross RJ; Merke DP
    Eur J Endocrinol; 2015 Dec; 173(6):727-37. PubMed ID: 26340969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
    El-Maouche D; Merke DP; Vogiatzi MG; Chang AY; Turcu AF; Joyal EG; Lin VH; Weintraub L; Plaunt MR; Mohideen P; Auchus RJ
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2771-8. PubMed ID: 32589738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia.
    Merke DP; Mallappa A; Arlt W; Brac de la Perriere A; Lindén Hirschberg A; Juul A; Newell-Price J; Perry CG; Prete A; Rees DA; Reisch N; Stikkelbroeck N; Touraine P; Maltby K; Treasure FP; Porter J; Ross RJ
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2063-e2077. PubMed ID: 33527139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia.
    Mallappa A; Nella AA; Sinaii N; Rao H; Gounden V; Perritt AF; Kumar P; Ling A; Liu CY; Soldin SJ; Merke DP
    Clin Endocrinol (Oxf); 2018 Oct; 89(4):399-407. PubMed ID: 30003563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Charmandari E; Johnston A; Brook CG; Hindmarsh PC
    J Endocrinol; 2001 Apr; 169(1):65-70. PubMed ID: 11250647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia.
    Sarafoglou K; Zimmerman CL; Gonzalez-Bolanos MT; Willis BA; Brundage R
    J Investig Med; 2015 Jan; 63(1):35-41. PubMed ID: 25386671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Study of Children Aged 0-8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules.
    Neumann U; Braune K; Whitaker MJ; Wiegand S; Krude H; Porter J; Digweed D; Voet B; Ross RJM; Blankenstein O
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1433-e1440. PubMed ID: 32888021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic innovations in endocrine diseases - Part 2: Modified-release glucocorticoid compounds: What good do they provide to the adrenal insufficient patient?
    Reznik Y
    Presse Med; 2016 Jun; 45(6 Pt 2):e205-10. PubMed ID: 27260966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion.
    Bryan SM; Honour JW; Hindmarsh PC
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3477-80. PubMed ID: 19567522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol secretion.
    Charmandari E; Pincus SM; Matthews DR; Johnston A; Brook CG; Hindmarsh PC
    J Clin Endocrinol Metab; 2002 May; 87(5):2238-44. PubMed ID: 11994370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
    Auchus RJ; Hamidi O; Pivonello R; Bancos I; Russo G; Witchel SF; Isidori AM; Rodien P; Srirangalingam U; Kiefer FW; Falhammar H; Merke DP; Reisch N; Sarafoglou K; Cutler GB; Sturgeon J; Roberts E; Lin VH; Chan JL; Farber RH;
    N Engl J Med; 2024 Aug; 391(6):504-514. PubMed ID: 38828955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.